Nirmal Singh, MD
Internal Medicine · Folsom, CANPI 1124408885
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $895 of the $1,150 with a category attached, or 77.8%. 9 manufacturers reported payments, led by Johnson & Johnson at 40.1% of the total. Reporting peaked in 2020 at $411 and has fallen 85.5% since, to $60 in 2024.
Across 54 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$461
- Astellas Pharma US Inc$198
- AstraZeneca$153
- Pfizer$121
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$101
- GSK$44
- plus $72 from 3 others
What the payments were for
- Food & beverage$89578%
- Education$25522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 26 | $461 |
| Astellas Pharma US Inc | 2 | $198 |
| AstraZeneca | 7 | $153 |
| Pfizer | 8 | $121 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $101 |
| GSK | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Boehringer Ingelheim | 1 | $24 |
| Baxter Healthcare | 1 | $23 |
How this compares
$1,150 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 12 | $4,405 |
| Midodrine Hcl | 19 | $2,134 |
| Carbamazepine | 12 | $1,486 |
| Rosuvastatin Calcium | 27 | $1,460 |
| Levetiracetam | 18 | $858 |
| Atorvastatin Calcium | 49 | $741 |
| Pantoprazole Sodium | 20 | $644 |
| Niacin ErNiacin | 12 | $602 |
| Tizanidine Hcl | 12 | $556 |
| Metformin Hcl | 52 | $534 |
| Gabapentin | 31 | $488 |
| Divalproex Sodium | 14 | $469 |
| Trazodone Hcl | 32 | $325 |
| Metoprolol Succinate | 11 | $267 |
| FenofibrateFenofibrate Nanocrystallized | 12 | $219 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Folsom
- Jaiwant RangiFolsom$548K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.